Division of Bacterial Diseases (DBD) News Bulletin
This website is archived for historical purposes and is no longer being maintained or updated.
April 16, 2013: Content on this page kept for historical reasons.
Amanda Cohn explained the Advisory Committee on Immunization Practices’ (ACIP) fall 2011 recommendation for a booster dose of meningococcal conjugate vaccine for adolescents in the 2012 Medscape video "Clarifying Meningococcal Booster Dose Recommendations."
Kathleen Dooling discussed pneumonia, preventive steps, and the need to stay up-to-date on vaccinations in her podcast on preventing pneumonia.
DBD 2012 Fast Facts
- 1 Joint Statment
- 2 Twitter Chats
- 3 Health Observances Celebrated
- 4 ACIP Votes
- 4 CDC Connects Articles
- 4 New EISO Officers
- 5 Tuesday Morning Seminars
- 5 Websites
- 6 Podcasts
- 8 Print Materials
- 15 International Lab Trainings
- 55 Human Subjects Actions
- 300+ Documents Cleared by ADS
Change in Administration for Anthrax Vaccine
Data from CDC’s Anthrax Vaccine Research Program (AVRP) provided the evidence for FDA approval in May of changes to the label for pre-exposure use of anthrax vaccine adsorbed (AVA, BioThrax). Under the new 3-dose primary series recommendation, AVA will safeguard 66% more personnel in one-third the time with an anticipated 50% reduction in local adverse events, and will require only half the number of doses compared with the original licensed schedule. It will also provide a significant cost reduction per schedule. FDA approval of a 3-dose primary series for AVA (BioThrax) represents the successful culmination of this CDC program. DBD/MVPDB will continue to work with the AVA manufacturer to explore additional reductions in the booster schedule. The Microbial Pathogenesis and Immune Response (MPIR) Laboratory and Brian Plikaytis from the Statistics Office made significant contributions to this research.
Tdap Vote: Streamlining the Adult Recommendation
In February, the Advisory Committee on Immunization Practices (ACIP) voted to recommend that all adults aged 19 years and older who have not yet received a dose of Tdap should receive a single dose. Tdap can be administered regardless of interval since last tetanus or diphtheria-toxoid containing vaccine.
- Page last reviewed: April 16, 2013 (archived document)
- Content source: